594P Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study

Ra-223 is a bone targeted alpha emitter approved for treatment of mCRPC on the basis of a significant survival advantage and favorable safety profile vs placebo in a phase III trial. Ra-223 also delayed opioid use and external beam radiotherapy vs placebo in post hoc analyses of that trial. PARABO (NCT02398526) is a prospective, observational, noninterventional, single-arm study evaluating pain efficacy in pts with mCRPC treated with Ra-223 in...